HCPCS Q0166: Granisetron 1 mg Oral Anti‑Emetic for Chemotherapy

HCPCS Level II code Q0166 identifies a 1 mg oral formulation of granisetron hydrochloride, an FDA-approved prescription anti-emetic used as a complete therapeutic substitute for an IV anti-emetic during chemotherapy, restricted to a 24-hour dosing regimen. This national-level billing descriptor matters because it enables documentation and billing for an oral alternative to intravenous anti-emetic therapy delivered at the time of chemotherapy, affecting care setting choices, medication administration workflows, and reimbursement pathways.

Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what Q0166 represents, the typical service line and site of service, and where this code fits in the clinical and billing landscape. The publication provides benchmarks and policy context relevant to billing and coverage for oral anti-emetics used as IV substitutes, outlines common billing modifiers and payer interactions (Data not available in the input), and clarifies the clinical scenario tied to chemotherapy-supportive care. The content is designed to help billing staff, practice managers, and policy analysts understand coding nomenclature, common operational uses, and areas where payer rules and site-of-service practices influence claim handling.

Billing Code Overview

HCPCS Level II code Q0166 describes granisetron hydrochloride, 1 mg, oral, an FDA-approved prescription anti-emetic intended for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, with dosing limited to a 24-hour regimen. The service type is oral anti-emetic medication administered in conjunction with chemotherapy. The typical site of service is oncology clinic or infusion center where chemotherapy is administered, or outpatient settings where patients receive chemotherapy and an oral substitute for IV anti-emetics.

Clinical Context

A typical patient is an adult or pediatric oncology patient receiving intravenous chemotherapy who requires an anti-emetic alternative when IV administration is not feasible or when a one-time oral substitute is clinically appropriate. The clinic verifies the chemotherapy schedule and orders oral granisetron hydrochloride Q0166 to provide anti-emetic coverage equivalent to a single-dose IV agent for up to 24 hours. Workflow: the oncology RN or pharmacist confirms patient identity, reviews recent anti-emetic response and allergies, documents indication (nausea and vomiting prophylaxis related to chemotherapy), obtains patient consent, dispenses the FDA-approved oral granisetron hydrochloride, 1 mg under the prescription direction, and documents administration or patient counseling in the medical record. Billing uses HCPCS Q0166 for the oral therapeutic substitute; applicable modifiers are appended per payer rules and the encounter note documents the substitution rationale and dose timing relative to chemotherapy infusion.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — default reporting	When no additional modifier is required by payer; rare, as most systems expect a numeric or alpha modifier.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Medical Oncology	Prescribers who commonly order anti-emetics for chemotherapy patients.
`208000000X`	Hematology/Oncology	Specialists managing chemotherapy regimens and supportive care.
`363A00000X`	Pharmacy	Clinical pharmacists involved in dispensing, substitution decisions, and medication counseling.
`207L00000X`	Internal Medicine	Hospitalists or internists who may manage inpatient oncology supportive care.
`207K00000X`	Family Medicine	Primary care clinicians involved in outpatient supportive medication management.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R11.0`	Nausea	Common symptom requiring anti-emetic prophylaxis or treatment during chemotherapy; indicates need for granisetron.
`R11.2`	Nausea with vomiting, unspecified	Acute presentation for which a one-time oral anti-emetic substitute may be used.
`C80.1`	Malignant neoplasm, primary site unknown — metastasis with unspecified site	Represents oncology patients receiving chemotherapy who require anti-emetic support.
`C50.9`	Malignant neoplasm of breast, unspecified	Example primary cancer diagnosis frequently treated with emetogenic chemotherapy where `Q0166` may be used.
`C34.90`	Malignant neoplasm of unspecified part of bronchus or lung	Another common chemotherapy indication associated with anti-emetic need.
`Z51.11`	Encounter for antineoplastic chemotherapy	Directly indicates chemotherapy encounter for which `Q0166` is used as an oral anti-emetic substitute.
`Z79.899`	Other long term (current) drug therapy	May be used when documenting ongoing supportive medication regimens in cancer care.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used when an injectable anti-emetic is administered instead of or prior to selecting an oral substitute; documents alternative route of administration in the workflow.
`96413`	Chemotherapy administration, IV infusion technique; each additional hour (List separately in addition to code for primary infusion)	Represents the chemotherapy infusion event for which `Q0166` is provided as anti-emetic coverage; documents the associated IV chemotherapy service.
`96417`	Chemo infusion — each additional sequential infusion (for complex multi-day regimens)	Used for complex chemotherapy regimens where anti-emetic substitution decisions are made per infusion segment.
`99212`	Established patient office or other outpatient visit, low complexity	Typical clinician visit level when discussing anti-emetic substitution and documenting counseling for outpatient chemotherapy.
`99406`	Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes	Example of a counseling code representing brief supportive care services; included as a commonly paired counseling activity though not specific to anti-emetic dispensing.

OpenPayer

Summary & Overview